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Abstract Metaplastic breast carcinoma (MBC) comprises a
heterogeneous group of tumors with difficult to predict biologi-
cal behavior. A subset of MBC, characterized by spindle-shaped
tumor cells with a myoepithelial-like immunophenotype, was
entered into a retrospective study (n = 42, median follow-up time
43 months). Molecular parameters (DNA sequences of mutation
hot spots in AKT1, ALK, APC, BRAF, CDH1, CTNNB1,
EGFR, ERBB2, FBXW7, FGFR2, FOXL2, GNAQ, GNAS,
KIT, KRAS, MAP2K1, MET, MSH6, NRAS, PDGFRA,
PIK3CA, PTEN, SF3B1, SMAD4, SRC, SRSF2, STK11,
TP53, and U2AF1; copy numbers for EGFR, c-myc, FGFR,
PLAG, c-met) were assessed. None of the patients had axillary
lymph node involvement. In 13 cases, local recurrence devel-
oped after surgery (30.9%). Distant metastasis occurred in seven
patients (17 %; four after local recurrence). The most frequent
genetic alteration was PIK3CA mutation (50 % of cases). None
of the pathological parameters (size, grade, stage, Ki-67 labeling
index) was significantly associated with disease-free survival
(DFS) or overall survival (OS). PIK3CA mutation, especially
the H1047R type, tended to adversely affect OS. Type of resec-
tion (mastectomy vs. breast-conserving therapy, width of mar-
gins) or adjuvant radiotherapy had no influence on DFS or OS,
whereas in the group treated with radio-/chemotherapy, no local
recurrence or metastasis and no death occurred. We conclude
that the spindle cell type of MBC with myoepithelial features
exhibits a higher frequency of PIK3CA mutation than other
types of metaplastic or basal-like breast cancer and may benefit
from combined radio-/chemotherapy. Classical pathological pa-
rameters are not helpful in identifying the high-risk tumors
among this subgroup of MBC.
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Introduction
Whereas prospective studies have identified prognostic factors
in invasive breast carcinoma of no special type, knowledge is
limited in the rare special types. Metaplastic breast carcinomas
(MBCs) comprise a heterogeneous group of neoplasms.
Whereas some MBCs are clearly high-grade tumors and are
easily recognizable as malignant, a considerable proportion of
spindle cell MBC can appear deceptively benign. These tumors
are often misdiagnosed as nodular fasciitis, fibromatosis, and
scarring reaction on the one hand or as low-grade sarcomas or
fibrosarcomas, on the other [1, 2]. This subset of MBC is com-
posed of neoplastic spindle cells with an immunophenotype
identical to myoepithelial cells [3–6]. Spindle cell
myoepithelial carcinoma (SCMC) is difficult to distinguish
from other spindle cell mammary neoplasms by light micros-
copy, and in most instances, immunohistochemistry is required
for its recognition. Many descriptive terms have been used
to classify this particular type of MBC, such as matrix-
producing carcinoma, carcinosarcoma, spindle cell carcino-
ma, and carcinoma with pseudosarcomatous metaplasia,
with metaplastic spindle cell or sarcomatoid breast cancer
being the most widely applied designations. The new
World Health Organization (WHO) classification (2012)
subdivides the rubric of MBC of spindle cell type into
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fibromatosis-like metaplastic carcinoma (8572/3), spindle
cell carcinoma (8032/3), and myoepithelial carcinoma
(8982/3) [7]. These lesions are considered to constitute a
continuum without definite criteria for discrimination.
Because the term MBC encompasses a group of diverse
tumors, it has been difficult to reliably predict biological po-
tential or to determine optimal therapy [8]. Despite their be-
nign appearance, spindle cell carcinomas of the breast have
been reported to exhibit aggressive behavior with a tendency
to progression similar to invasive duct carcinomas [9].
Histological features such as grade, cellularity, mitotic activi-
ty, differentiation of the carcinoma, presence of squamous
epithelium, and degree of inflammation were not found to
predict outcome [10]. Including the cytologically bland
fasciitis-like variant, spindle cell MBCs were found by some
investigators to be highly aggressive neoplasms with a high
rate of extra-nodal metastases [8, 11, 12], although they may
have a significantly lower rate of nodal metastases than con-
ventional ductal or lobular carcinomas [8, 11, 13]. Other stud-
ies reported that the spindle cell phenotype appears to behave
less aggressively when compared to the whole group of MBC
[13], and no distant metastasis was found in a small series of
10 cases [14].
Up to now, only little is known about the somatic mutations
which give rise to SCMC. Studies are hampered by the het-
erogeneity of MBC and only rarely have correlations of mo-
lecular findings with the histologic subtypes within this rubric
of mammary neoplasms been undertaken. Biphasic and
monophasic types of MBC have been lumped together [15].
Accordingly, it was found that MBC constitutes a heteroge-
neous group of tumors also in terms of their gene copy number
aberrations and transcriptomic profiles [16]. Genetic changes
of Wnt pathway genes have been found as common events in
MBC [17]. This could not be confirmed by Lacroix-Triki et al.
[18] who identified no CTNNB1 mutation in any of the 21
MBCs. A high copy number of EGFR via aneusomy has been
described [19]. Overexpression of EGFR by MBC is partly
caused by gene amplification without evidence of activating
mutations within the EGFR gene [20]. Frequent aberrations of
the p53 tumor suppressor gene were found to characterize
MBC [15, 21]. In the case of bimodal differentiation, both
components shared p53 mutation indicating that the gene is
altered at an early stage of clonal expansion [15, 21].
In this study, we focused on one special subtype of MBC
which is composed of spindle cells, demonstrating matrix
production and a myoepithelial immunophenotype.
Recently, we could show that these types of cancer reveal a
miRNA profile which is identical to normal myoepithelial
cells whereas non-spindle cell carcinomas with expression of
basal markers resembled luminal cells [22]. Non-spindle so
called basal carcinomas and carcinosarcomas with an accom-
panying invasive adenocarcinoma component were excluded
from the study.
Patients, materials, and methods
All cases in this retrospective study (n = 42) were sent to the
reference center for breast pathology in Hannover, Germany, for
histopathological consultation between 1999 and 2014. Tumors
composed of a predominant spindle cell population with matrix
production featuring a myoepithelial immunophenotype (posi-
tive for cytokeratins 5/14 and/or p63/p40 in at least 10 % of
tumor cells) and infiltrative growth were included. Non-
infiltrative lesions with myoepithelial characteristics, such as
adenomyoepithelioma, and malignant tumors featuring invasive
glandular components or heterogeneous elements except for foci
of squamous differentiation were excluded. Representative par-
affin blocks were used for all further studies. Tissue frommetas-
tases was available in three cases and from local recurrences in
four cases, respectively. Clinical information was retrospectively
gathered from the requesting hospitals and the patients’ general
practitioner or registered gynecologist.Written informed consent
was obtained from all patients entering the study, or their respec-
tive familymembers or legal guardian. The study was confirmed
by the Ethic Committee of Hannover Medical School.
Patient (age, menopausal status) and tumor (size, nodal
status, metastasis) characteristics as well as types of treatment
(breast-conserving surgery vs. mastectomy, width of margins)
and adjuvant therapies (chemotherapy, radiotherapy) were
assessed. The clinical course was evaluated with regard to
disease-free (occurrence of local recurrence and distant metas-
tasis) and overall survival. Mean follow-up interval was
43 months (range 9 to 167 months). One patient known to
have a co-existing malignant disease at the time of diagnosis
was excluded from follow-up evaluation.
Immunophenotyping
For immunohistochemistry, 2-μm sections of formalin-fixed
paraffin-embedded (FFPE) tumor specimens were mounted
on poly-L-lysine-coated slides and deparaffinized and
rehydrated conventionally. Immunohistochemical stainings
were performed on a Benchmark Ultra (Ventana, USA) auto-
mated stainer using the CC1-mild or CC1-st protocols for target
retrieval and the anti-CD10 (clone 56C6, Thermo Scientific,
Germany, 1:10), anti-CD34 (clone QBEnd/10, Leica
Biosystems, Germany, 1:50), anti CK5/14 (clone XM26/
LL002, Zytomed Systems, Germany, 1:100), anti-CK8/18
(clone 5D3, Leica Biosystems, 1:100), anti-p63 (clone Y4A3,
Zytomed Systems, 1:50), anti-p40 (rabbit polyclonal, PC373,
Calbiochem, U.S.A., 1:1000), anti-smActin (clone 1A4, Dako,
Denmark, 1:100), anti-EGFR (clone 2-1E1, Zytomed Systems,
1:200), anti-ER (clone SP1, Ventana, 1:1), anti-PR (clone 1E2,
Ventana, 1:1), anti-HER2 (clone 4B5, Ventana), and anti-Ki-67
(clone SP6, Thermo Scientific, 1:100) antibodies. Besides char-
acteristic histomorphology, at least two of the three
myoepithelial markers (CK5/14, p63 or p40, CD10) being
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positive in more than 10 % of tumor cells were required for
inclusion into the study.
Fluorescence in situ hybridization
Representative formalin-fixed paraffin-embedded cores (2 per
case, each 1.4mm2) from each of the tumors (n = 42) were built
into a tissue microarray (TMA) for fluorescence in situ hybrid-
ization (FISH). FISH studies were performed following stan-
dard protocol on 3-μm-thick unstained sections, mounted on
Super Frost Plus slides (Menzel, Germany). Slides were dried
in a Heraeus dry incubator (ThermoScientific) at 60 °C for 1 h
and subsequently pretreated by dewaxing with xylene supple-
mentation (AppliClear, AppliChem, Germany), followed by
rehydration in ethanol in descending concentrations (100, 85,
and 70 %). Specimens were then permeabilized and denatured
in a microwave oven for 30 min with sodium citrate buffer (pH
6.0) (Sigma Aldrich, USA), cooled to room temperature, and
rinsed in distilled water. This was followed by incubation with
a pepsin solution for 15 min at 37 °C and subsequently passed
through ascending concentration of ethanol (70, 80, and
100 %). Hybridization was started by using different FISH
probes to analyze for abnormalities of the genes c-myc, c-met,
EGFR, FGFR1 [23], and PLAG1 [24] (ZytoLight SPEC
CMYC/CEN8 Dual Color Probe, ZytoVision, Germany;
ZytoLight SPEC CMYC/CEN8 Dual Color Break Apart,
ZytoVision; ZytoLight SPEC MET/CEN7 Dual Color Probe,
ZytoVision; ZytoLight SPEC EGFR/CEN7 Dual Color Probe,
ZytoVision; ZytoLight SPEC FGFR1/CEN8 Dual Color
Probe, ZytoVision and PLAG1 FISH probe, Abnova).
Specimens were heated to 80 °C for 10 min to denature the
probe and specimen DNA and incubated overnight at 37 °C in
a ThermoBrite slide processing system (Abbott). Subsequently,
specimens were washed in 0.4×SSC (sodium chloride sodium
citrate, Abbott) at 75 °C for 2 min and passed through ascend-
ing concentrations of ethanol (70, 85, and 100 %). Finally,
slides were counterstained with DAPI (4′,6-diamidin-2-
phenylindol) 40 ng/ml (Qiagen, Netherlands). At least 100
non-overlapping interphase tumor cell nuclei with hybridiza-
tion signals were evaluated for each case with a fluorescence
microscope (Olympus BX51) at a ×630/1000 magnification
(oil immersion objective). Thresholds for aberrant counts were
defined for each probe according to the manufacturer’s speci-
fications and our established procedure.
DNA sequencing
From tumor-bearing paraffin blocks, 5-μm-thick sections
were cut and tumor infiltrates were enriched by microdissec-
tion. From each specimen, two to six sections were taken,
depending on tumor size. Genomic DNAwas extracted from
FFPE specimens with DNeasy Blood & Tissue Kit (Qiagen)
according to the manufacturer’s recommendations. DNA
quantification was performed using the Qubit 2.0
Fluorometer with dsDNA high sensitivity Assay kit (Life
Technologies). In total, DNA from 36 patients was available
and in an amount and quality adequate for sequencing. For
initial screening of the study cohort, 13 samples were analyzed
with the Illumina TruSight™ Tumor Sequencing Panel
(Illumina). Median of the mean sequencing depth for these
13 patient samples was 1506 reads (range 175–4885). To val-
idate results, six of these samples plus additional 23 patients
were analyzed with Ion AmpliSeq™ Colon and Lung Cancer
Research Panel v2 with a median ofmean sequencing depth of
3185 reads (range 819–6595). The TruSight™ Tumor
Sequencing Panel (Illumina) comprises 175 amplicons of 26
genes (AKT1, ALK, APC, BRAF, CDH1, CTNNB1, EGFR,
ERBB2, FBXW7, FGFR2, FOXL2, GNAQ, GNAS, KIT,
KRAS, MAP2K1, MET, MSH6, NRAS, PDGFRA, PIK3CA,
PTEN, SMAD4, SRC, STK11, and TP53) with relevance in
different types of cancer. Amplicon size was between 165
and 196 Bp. Amplicon-based library preparation requires
100 ng purified genomic DNA. Sequencing was performed
on a MiSeq Instrument with MiSeq Reagent Kit v2
(300 cycles) (Illumina) with 10 samples on a flow cell. The
Ion AmpliSeq™ Colon and Lung Cancer Research Panel v2
(Life Technologies) comprises 92 amplicons from the hotspot
regions of 19 genes (AKT1, ALK, BRAF, CTNNB1, DDR2,
EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3,
KRAS, MAP2K1, MET, NOTCH1, NRAS, PIK3CA, PTEN,
STK11, and TP53) which are well-described to be of relevance
in different types of cancer, including breast cancer [23, 25,
26]. The panel is designed for FFPE DNA and requires 10 ng
of input material. Amplicon target region lengths were be-
tween 51 and 137 Bp. Library preparation was performedwith
the Ion AmpliSeq Library Kit 2.0 (Life Technologies).
Quantitation of the libraries was conducted by qPCR with
the Ion Library Quantitation Kit (Life Technologies). For tem-
plate preparation in the Ion OneTouch 2 instrument (Life
Technologies), eight patient samples were pooled (100 pM
each). Sequencing was performed on the Personal Genome
Machine (PGM) with Ion PGM Sequencing 200 Kit v2 on
316 v2 chips (all Life Technologies). Analyses of sequencing
raw data were performed with Torrent server software version
4.2.1 (Life Technologies), IGV-Browser Version 2.3.34
(http://broadinstitute.org/igv/), and Cartagenia Bench Lab
NGS software version 3.1.2 (Cartagenia). Parameters for
analysis exclude single nucleotide variants with an allele
frequency <2 % and complex mutations with an allele
frequency <5 %, and a quality score (PHRED-scaled
probability of incorrect calls) below 100. In addition, the study
cohort was analyzed by Sanger sequencing on GenomeLab™
GeXP capillary sequencer (Beckman Coulter) to verify vari-
ants reported from targeted next-generation sequencing
(NGS) and to analyze splice factor genes [26]. Sanger se-
quencing was performed on exon-coding sequences of
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PIK3CA (exons 1, 3, 7, 8, 9, and 20), TP53 (exons 5–8),
SRSF2 (exon 1), U2AF1 (exons 2 and 6), and SF3B1 (exons
14 and 15) [27]. PCR amplification of DNA was done in a
total volume of 25 μl PCR mix containing 10–50 ng template
DNA, Taq buffer, 2.5 mM MgCl2, 200 μmol of each
deoxynucleotide triphosphate, 10 pmol of each primer, and
0.5 U of Invitrogen™ Platinum Taq (Life Technologies).
PCR amplification conditions were as follows: 95 °C
10 min; 95 °C 30 s, 60 °C 45 s, 72 °C 30 s for 40 cycles;
72 °C 10 min. The sequence data files were analyzed with
SeqMan Pro software version 8.1.4 (DNASTAR®).
Statistical methods
A survival analysis was carried out to describe clinical outcome
and to identify possible variables with prognostic value. Time
from surgery to death due to any cause was considered of pri-
mary interest. In addition, disease-free survival (defined as time
from surgery to occurrence of local recurrence or distant metas-
tasis) was evaluated. Patients were censored at the time of their
last contact with the investigators in case of no event. Kaplan-
Meier plots were used to display the course of survival, and the
log-rank was calculated to test for differences of the survival
functions. Based on the Kaplan-Meier estimates, the median
survival time and its 95 % confidence interval were calculated
if possible. The mean ± SE was also calculated; however, the
mean values may be biased downward as the censoring timewas
greater than the largest observed event time.
A Cox PH model was set up for overall and disease-free
survival. The proportional hazard assumptionwas checked via
the cumulative sums of martingale residuals and the calcula-
tion of Schoenfeld residuals. In a first step, we assessed the
impact of each of the covariables on the survival time sepa-
rately. Additionally, we tried to find a suitable fractional poly-
nomial with the help of the %mfp8 macro (available from
https://portal.uni-freiburg.de/imbi/mfp/) to check for a
possible non-linear relationship. Subsequently, a multiple re-
gression model was set up involving variables considered of
importance based on the univariate analysis. In this model, a
backward-selection approach was applied to remove non-
informative variables. Due to the explorative nature of this
study, no multiplicity adjustments were performed, and thus,
the type I error rate could not be controlled.
The statistical analysis was carried out with SAS 9.3 soft-
ware (SAS Institute Inc., USA).
Results
Patient and tumor characteristics and outcome
Forty-two patients, aged 39–92 years (median 74 years), were
included in the study. All patients had presented with a
palpable, singular nodule of the breast. Tumor size was known
in 41 cases and varied from 5 to 85 mm (median 30 mm). One
tumor showed infiltration of the pectoral muscle, and all other
lesions were confined to the breast and were categorized as
pT1–pT3 according to the TNM classification of breast tu-
mors (pT1 ≤ 20 mm; n = 11, pT2 > 20–50 mm; n = 24,
pT3 > 50 mm; n = 6). No patient had lymph node involve-
ment, as assessed either by sentinel node examination
(n = 20), axillary dissection (n = 11), or ultrasound imaging
(n = 10). No patient had evidence of distant metastasis at time
of diagnosis. Consequently, all patients were treated surgically
as a curative approach.
Forty-one patients could be evaluated. Median time of
follow-up was 43 months (range 9–167 months). Median sur-
vival time was 76 months (mean ± SE, 61.4 ± 3.9 months) for
overall survival. For disease-free survival, a mean time of
34.5 ± 2.7 months was observed. Within the observed time
period, 12 (29.3 %) patients died due to any cause, and in 16
patients (39.0 %) relapses were noted (Fig. 1a, b). Nine pa-
tients (21.4%) had local recurrence but did not develop distant
metastasis. After a median follow-up of 5 years (61 months,
range 16–167 months) after the initial procedure, all nine pa-
tients with local recurrence were alive with no evidence of
disease. Local recurrence occurred after a median time of
10 months (range 5–37 months), and all patients received
surgical revision. One patient had another tumor relapse after
11 months, but remained disease-free after another resection
during the 22-month follow-up. Seven patients (17.1 %) de-
veloped distant metastasis with or without (n = 3) prior or
simultaneous diagnosis of local recurrence. Median time until
development of distant metastasis was 16 months (6–
47 months). All patients in this group died within a period of
9–53 months after the initial operation (median 29 months).
The most common sites of distant metastasis were lungs,
bones, and liver (Table 1).
Correlation of clinical and pathological parameters
with outcome
DFS and OS did not differ significantly in patients <74 years
compared to patients 74 years and older (Table 2). Tumors
≤20mm (pT1) had a lower rate of local recurrence, metastasis,
and death compared to tumors >20 mm (pT2, pT3) (hazard
ratio 2.82 for DFS and 3.28 for OS for tumors >20 mm), but
the difference was not statistically significant. There were also
no significant differences when tumors ≤50 mm (pT1, pT2)
were compared to tumors >50 mm (pT3) (Table 2).
All cases were characterized by proliferation of spindle cells
with slender nuclei in varying densities. Typically, the spindle
cells infiltrated around pre-existing ducts and lobuli (Fig. 2a–c).
Matrix production was heterogeneous within single tumors and
ranged from loose to dense connective tissue (Figs. 2b, 2c and
3a). Some cases exhibited pseudoangiomatoid spaces due to
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mucoid change of intercellular matrix with an endothelial-like
inner cell layer around themucoid material (Figs. 2a and 3b). In
f ive cases , bes ides the sp ind le ce l l t umor, an
adenomyoepithelioma was found, which probably represented
the lesion of origin. In other four tumors, foci of squamous
differentiation not exceeding 10 % of tumor cells were seen
(Fig. 2c). Both features appeared not to be associated with
higher risk of recurrence. In metastasis, the spindle cell mor-
phology and immunophenotype were retained but the cellular-
ity appeared to be denser than in the original tumor (Figs. 2d
and 3d). Tumor cells were classified G1 in 10 cases (23.8 %),
G2 in 24 cases (57.1 %), and G3 in eight cases (19 %). The rate
of events was similar in the G1 and G3 groups. Mean disease-
free and mean overall survival were longer in the G1 group
Fig. 1 Kaplan-Meier plots of
disease-free survival (a) and
overall survival (b) in a cohort of
41 patients with spindle cell
myoepithelial carcinomas
(SCMCs)
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compared to the G3 group (29 vs.10 months and 69 vs.
57 months), but the difference was not statistically significant
(Table 2).
The Ki-67 labeling index ranged from 5 to 70 % (median
25 %), 19 tumors exhibited a Ki-67 labeling index from 5 to
20 %, 18 tumors from 25 to 40 % (Fig. 3c), and five tumors
from 50 to 70 %. A higher Ki-67 labeling index, exceeding
20 %, was associated with a shortened disease-free survival
but not overall survival (HR 0.51, log-rank test 0.06; Table 2).
All tumors were negative for ER, PR, and HER2. The most
frequently expressed myoepithelial markers were CD 10
(Fig. 3b), SM-actin, CK 5–14 (Fig. 3d), and P63/P40
(Fig. 3a), whereas CK 8–18 was negative in the majority of
tumors and CD34 was negative in all cases tested (n = 15)
(Table 3).
Molecular findings
Copy numbers for EGFR, c-myc, FGFR, PLAG, and c-met
were determined by fluorescence in situ hybridization using
tissue microarrays. No significant copy number aberrations
were found. Targeted DNA sequencing revealed a high fre-
quency of PIK3CA mutation (18 out of 36 samples; 50 %;
mean sequencing depth 4575 reads, range 1135–8128 reads).
All mutations were confirmed by Sanger sequencing. The
H1047R mutation was the most frequent type (Table 4).
PIK3CA mutation altogether and especially the H1047 type
tended to be associated with a shorter DFS and OS. In the
PIK3CA-mutated group DFS was 14 months and in the
PIK3CA-wild type group 34 months (log-rank test
p = 0.94). With regard to OS, the difference between the two
groups was 41 vs. 60 months (log-rank test p = 0.241, HR
2.16). In the 12 patients with H1047R mutation, mean DFS
was shortened from 35 to 13 months (log-rank test p = 0.56,
HR 1.38) and OS from 60 to 38 months (log-rank test
p = 0.15, HR 2.59). All other molecular aberrations assessed
in this retrospective study, including TP53, occurred only in a
minority of cases or were not associated with OS or DFS.
Mutations of TP53 were observed in three out of 30 cases
(10 %; K132T; R196Q; P72fs). Mutation of EGFR (G735S
and A871T) was found in two cases and of c-met in other two
out of 30 cases (E168D and T1010I) (Table 4). No mutations
were discovered by targeted sequencing of AKT1, ALK,
BRAF, CTNNB1, ERBB2, FBXW7, FGFR2, KRAS,
MAP2K1, NRAS, PTEN, and STK11 (represented in both
panels). CDH1, FOXL2, GNAQ, GNAS, KIT, MSH6,
PDGFRA, SMAD4, and SRC, covered only by the Illumina
platform (n = 13), and DDR2, ERBB4, FGFR1, FGFR3, and
NOTCH1, covered only by the Life Technology platform
(n = 29), respectively, were also not mutated. Conventional
pyro- and Sanger sequencing revealed SF3B1 mutation in two
cases (E622K, L707*), whereas other RNA splice factor
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Types of treatment
Mastectomywas performed in 18 patients, and 23 patients had
breast-conserving therapy. In the mastectomy group, both
DFS and OS did not differ significantly compared to the less
radical procedure (Table 2). Tumor-free margins were indicat-
ed by the referring pathologist in 29 cases and unknown in 13
of the surgical specimens (mastectomies in eight cases).
Tumor-free margins ranged from 0 to 25 mm (median
3 mm). Tumor tissue reached the sample margin in two cases
(B0 mm^), but the R0 situation was affirmed by the surgeon.
Patients who were resected with a surgical margin < 5mm
were compared with those who had a margin > 5mm
(Table 2). Event rates were similar and no significant differ-
ence was found regarding DFS and OS. Axillary dissection
was conducted in 11 patients and had no significant influence
on DFS or OS. Twenty-three patients had no adjuvant therapy,
10 received radiotherapy alone, and seven patients had com-
bined radio-/chemotherapy. In two patients, no information on
adjuvant therapies was available.
In those patients who had received combined radio- and
chemotherapy, no local recurrence, no metastasis, and no death
occurred. Radiotherapy and the combined radio- and chemo-
therapy were compared to no treatment with respect to DFS or
OS (log-rank test; DFS p = 0.0507, OS p = 0.0715) (Table 2).
In a pairwise comparison, only the combination of radio- and
chemotherapy had a statistically significant influence (log-rank
test; DFS p = 0.015, OS p = 0.079) (Table 2).
For multivariate analysis, a multivariable regression model
was set up with types of treatment (BCT vs. mastectomy), adju-
vant therapies and PIK3CA as independent covariables. In a
stepwise (entry criterion p < 0.25, retaining criterion p < 0.2)
and a backward (retaining criterion p < 0.2) model selection
process, none of the covariables was retained in either model.
Discussion
Rare types of breast cancer usually provide a challenge be-
cause no prospective therapy trials, as in breast cancer of no
Table 2 Patient data and outcome
Parameter Disease-free survival [months] Overall survival [months]




<74 years(1) (n = 21)(2)
≥74 years (n = 20)(2)
26.0 ± 3.0
38.3 ± 3.7
0.3156 0.60 (0.20, 1.62) 35.4 ± 2.0
60.7 ± 5.4




≤50 mm(1) (n = 34)(2)
>50 mm (n = 6)(2)
34.7 ± 2.9
6.0 ± 0.0
0.7194 1.31 (0.20, 4.77) 58.9 ± 3.6
40.7 ± 8.2
0.3578 2.03 (0.31, 8.00)
≤20 mm(1) (n = 10)(2)
>20 mm (n = 30)(2)
34.1 ± 3.9
31.6 ± 3.4
0.1505 2.82 (0.79, 17.97) 39.0±–
55.2 ± 4.3
0.2294 3.28 (0.63, 60.25)
Grading G1(1) (n = 10)(2) 29.2 ± 4.4 0.9536(3) 69.4 ± 8.7 0.4802(3)
G2 (n = 23)(2) 34.5 ± 3.8 0.7818 1.16 (0.38, 4.30) 45.4 ± 2.9 0.2424 2.60 (0.61, 17.77)
G3 (n = 8)(2) 10.3 ± 0.7 0.9856 0.99 (0.20, 4.49) 57.1 ± 9.6 0.3791 2.22 (0.37; 16.93)
Ki67% ≤20(1) (n = 19)(2) 30.2 ± 4.1 0.0604 57.3 ± 5.6 0.1951
>20 (n = 22)(2) 27.7 ± 2.2 0.51 (0.19, 1.44) 64.2 ± 4.7 1.49 (0.46, 5.69)
PIK3CA No mutation (n = 18)(2) 34.4 ± 3.8 0.9397 60.0 ± 5.0 0.2413
Mutation (n = 18)(2) 13.5 ± 1.1 0.96 (0.32, 2.68)(5) 41.1 ± 3.4 2.16 (0.57, 8.82)
No mutation (n = 24)(2) 35.1 ± 3.4 0.5564 59.9 ± 4.3 0.1447
H1047R mutation (n = 12)(2) 13.2 ± 1.3 1.38 (0.43, 3.96)(5) 38.4 ± 4.6 2.59 (0.63, 9.96)
Surgery BCT(1) (n = 23)(2) 28.0 ± 2.8 0.7733 61.6 ± 4.2 0.1909
Mastectomy (n = 18)(2) 35.9 ± 4.5 0.86 (0.29, 2.33) 55.9 ± 6.8 2.12 (0.67, 7.20)
Margin <5 mm (n = 16)(2) 27.6 ± 3.4 0.7707 44.8 ± 2.5 0.4963
Margin ≥5 mm (n = 22)(2) 32.3 ± 5.7 1.18 (0.38, 3.54) 47.2 ± 4.7 1.73 (0.32, 9.42)
Adjuvant therapy None(1) (n = 22)(2) 31.0 ± 3.8 0.0507(3) 57.6 ± 5.3 0.0715(3)
Radiotherapy (n = 10)(2) 14.0 ± 1.5 0.1715 0.62 (0.14, 1.97) 57.1 ± 9.1 0.4120 0.82 (0.18, 2.85)
Radio−/chemoth. (n = 7)(2) N.E. 0.0154 N.E. N.E. 0.0790 N.E.
(1) = Reference category chosen for the Cox PHmodel, (2) = case number, (3) = global. Median survival was calculated according to the Kaplan-Meier
method. Calculation ofmedian survival and its upper or lower confidence interval limits or SE were not always possible. These cases are indicated as (–).
There were no events in the Radio−/Chemotherapy group (N.E.). In some models, the Cox PH assumption may not be met (5). For variables with 3
groups, a global log-rank test was performed as well as pairwise comparisons with a reference
CI confidence interval, HR hazard ratio, BCT breast-conserving therapy, SE standard error
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special type, are available. Data from studies on breast cancer
of no special type cannot simply be extrapolated and trans-
ferred to the rare subtypes. MBC represents a rare subtype and
is in itself heterogeneous. AmongMBC, there is a subgroup of
pure spindle cell tumors with a myoepithelial-like phenotype
(SCMC) [3–6]. It has been reported previously that, despite
their benign appearance, spindle cell carcinoma of the breast
shows aggressive behavior and progresses in a fashion similar
to that of invasive duct carcinomas of no special type [8, 9, 11,
12]. The retrospective series presented here confirms the po-
tentially aggressive course. Cumulative event rate regarding
local recurrence or metastasis amounted to 39.0 %, and the
Fig. 2 Spindle cell myoepithelial
carcinomas (SCMCs) were char-
acterized by proliferation of spin-
dle cells with slender nuclei in
varying densities, infiltrating
around pre-existing ducts and
lobuli (a–c). All tumors exhibited
matrix production but to varying
extents (a, b). Due to mucoid
change of intercellular matrix,
pseudoangiomatoid spaces oc-
curred in some cases (a, lower left
quadrant) with an endothelial-
like inner cell layer around the
mucoid material. Occasionally,
foci of squamous differentiation
not exceeding 10% of tumor cells
were found (c). Brain metastasis
retained spindle cell morphology
but revealed a higher cell density
(d) (a–d, hematoxylin-eosin
stain)
Fig. 3 The myoepithelial marker
P63 was present in the nuclei of
spindle cells in SCMC (a). CD10
was expressed in nearly all cases
whereby spindle cells as well as
endothelial-like cells around cys-
tic spaces exhibited positive la-
beling (b). Despite the bland
morphology of spindle cell pro-
liferates in SCMC, most cases
showed a Ki-67 labeling index
exceeding 10 % (c). High molec-
ular weight cytokeratin (5, 14),
which characterizes myoepithelial
cells, was expressed by SCMT
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cumulative event rate regarding death of any cause reached
29.2 %. In addition, a finding made previously by Oberman
et al. [10] was confirmed by this study. Conventional histo-
pathological parameters, such as grade, mitotic activity, and
presence of squamous epithelium, were not related to outcome
(Table 2), although it cannot be excluded that the number of
cases was too small to demonstrate a significant association.
Missing or low rate of nodal metastases, as found in this se-
ries, was also reported by others [8, 11, 13]. Although we
present one of the largest series of this special type of meta-
plastic breast cancer, published so far, the case number was
too small to identify significant prognostic markers in the
chosenmultivariable regressionmodel, and potential prognos-
tic markers retained significance only in the univariate
analysis.
Up to now, only little is known about the somatic mutations
which give rise to SCMC. Molecular studies conducted on
MBC are hampered by the heterogeneity and diversity of
MBC. Only rarely have correlations of molecular findings
with the histologic subtypes within this rubric of mammary
neoplasms been undertaken. Biphasic and monophasic types
of MBC have been lumped together [15]. Accordingly, it was
found that MBC constitutes a heterogeneous group of tumors
also in terms of their gene copy number aberrations and
transcriptomic profiles [16]. Genetic changes of Wnt pathway
genes have been found as common events in metaplastic car-
cinomas of the breast [17]. This could not be confirmed by
Lacroix-Triki et al. [18] who identified no CTNNB1 mutation
in any of the 21 metaplastic carcinomas. A high copy number
of EGFR via aneusomy has been described [19].
Overexpression of EGFR by MBC is partly caused by gene
amplification without evidence of activating mutations within
the EGFR gene [20]. In contrast to other types of MBC, the
subtype under study here did not show EGFR gene amplifi-
cation, and EGFR gene mutation rarely occurred (n = 2).
Frequent aberrations of the p53 tumor suppressor gene char-
acterize metaplastic breast cancer [15, 21]. In the case of bi-
modal differentiation, both components shared p53 mutation
indicating that the gene is altered at an early stage of clonal
expansion [15, 21]. In SCMC, p53mutation appears to be less
frequent and we observed p53mutation in only 10% of cases.
The PI3K catalytic isoform p110α is the second most fre-
quently mutated oncogene. It belongs to the PI3K/AKT/
mTOR (phosphatidylinositol 3 kinase/Akt/mammalian target
of rapamycin) signaling cascade, which is downstream of
EGFR and plays a crucial role in diverse cellular processes
such as cell growth, survival, proliferation, and migration.
Table 3 Immunohistochemical
features of cases Antigen 0 % positive cells −10 % positive cells ≥10 and <50 %
positive cells
≥50 % positive cells
CD10 (n = 41) 1 0 1 39
CD34 (n = 15) 15 0 0 0
CK5/14 (n = 42) 1 3 3 35
CK8/18 (n = 41) 25 4 6 6
P63 (n = 42) 1 0 4 37
P40 (n = 40) 1 3 6 30
SM-actin (n = 41) 1 1 1 38
EGFR (n = 39) 1 4 4 30
ER (n = 42) 42 0 0 0
PR (n = 42) 42 0 0 0
HER2 (n = 42) 42 0 0 0
Ki-67 (n = 42) 0 6 31 5
Table 4 Gene mutations in SCMC
Gene Mutation Number % of cases studied










MET None 28/30 93.3
E168D 1 3.3
T1010I 1 3.3
EGFR None 28/30 93.3
G735S 1 3.3
A871T 1 3.3
SF3B1 None 28/30 93.3
E622K 1 3.3
L707* 1 3.3
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PI3K mutation proved to be the most frequent somatic muta-
tion detectable in breast cancer, particularly in luminal breast
cancer [23, 26]. By contrast, it seems to be considerably rarer
in the basal type or triple negative type [23]. In this respect, the
myoepithelial-like spindle cell metaplastic carcinoma seems
to be more similar to the luminal type, with a high proportion
of PI3KCA-mutated cases ranging to 50 %. As novel agents
antagonizing mutated PI3KCA enter clinical trials and show
encouraging clinical activity, in particular with regard to the
H1047 mutation [28], the blockade of the PI3K/AKT/mTOR
pathway could be a potential treatment option for this subtype
of MBC. Luminal expression of PIK3CA mutant H1047R in
mice induced adenomyoepithelial-like tumors [29] which
could partly reflect the pathogenesis of myoepithelial-like
spindle cell MBC, which can evolve from intraductal
adenomyoepithelial tumors. In concordance with this specu-
lation, intraductal papilloma to which adenomyoepithelial tu-
mors are related revealed a high frequency of PI3K/AKT mu-
tation [30].
Whereas all patients in this series received surgical therapy,
only a minority (n = 7) was treated by chemotherapy. A po-
tential reason for the restraint of clinicians to perform adjuvant
chemotherapy may be given by the histologically low-grade
aspect of SCMC and the lack of study data on this rare type of
MBC. Although the number of adjuvantly treated patients in
our series of SCMC is small, there is significant evidence that
SCMC patients might benefit from adjuvant chemotherapy. A
potential benefit of adjuvant chemotherapy was also noted in a
large retrospective study including all types of MBC [31].
Currently, there are no reliable criteria available to identify
the high-risk subgroup among SCMC which will progress
and metastasize. Further molecular investigations beyond the
genes analyzed in this study may uncover molecular markers
of progression. The frequent activation of the PI3K/AKT/
mTOR pathway by PI3K mutation in SCMC might represent
a druggable genetic aberration.
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